Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Prepaid Assets (2016 - 2026)

Insight Molecular Diagnostics' Prepaid Assets history spans 7 years, with the latest figure at $1.4 million for Q4 2025.

  • On a quarterly basis, Prepaid Assets rose 72.96% to $1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 million, a 72.96% increase, with the full-year FY2025 number at $1.4 million, up 72.96% from a year prior.
  • Prepaid Assets hit $1.4 million in Q4 2025 for Insight Molecular Diagnostics, up from $1.2 million in the prior quarter.
  • Over the last five years, Prepaid Assets for IMDX hit a ceiling of $2.3 million in Q3 2021 and a floor of $8000.0 in Q1 2021.
  • Historically, Prepaid Assets has averaged $1.1 million across 5 years, with a median of $1.1 million in 2022.
  • Biggest five-year swings in Prepaid Assets: plummeted 99.15% in 2021 and later surged 18837.5% in 2022.
  • Tracing IMDX's Prepaid Assets over 5 years: stood at $901000.0 in 2021, then increased by 8.44% to $977000.0 in 2022, then plummeted by 34.19% to $643000.0 in 2023, then increased by 27.68% to $821000.0 in 2024, then surged by 72.96% to $1.4 million in 2025.
  • Business Quant data shows Prepaid Assets for IMDX at $1.4 million in Q4 2025, $1.2 million in Q3 2025, and $1.3 million in Q2 2025.